// App-Quantinova.ai

676 : R115777(tipifarnib) Improves Early Survival when Used As Maintenance Therapy for Elderly or Relapsed/Refractory Patients with Acute Myelogenous Leukemia in Remission

Researchers

Presenter

  • Lynette Zickl

Principal Investigators

  • Elisabeth Paietta

  • Rhett P Ketterling

  • Hillard M Lazarus

  • Witold Rybka

  • Mark R Litzow

  • Jacob M Rowe

  • Richard A. Larson

  • Martin S. Tallman

Medical Centers

  • Hematology/Oncology and Comprehensive Cancer Center, University of Chicago, Chicago, IL

  • Rambam Medical Center, Haifa, Israel

  • Abramson Cancer Center and Department of Medicine, University of Pennsylvania,, Philadelphia, PA.

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • United States

  • Israel

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Acute myelocytic leukemia

  • Acute lymphoblastic leukemia

  • Thrombocytopenia

  • Neutropenia

Biomarkers

  • N/A

Drug/Treatment

  • Tipifarnib

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved